price
NYSE · PFE
Pfizer Inc.
Healthcare · Drug Manufacturers - General
$27.96
Down-$0.06 (-0.21%)
Updated Aug 31, 2026, 8:27 AM
SID Score
7.5/10
Composite research score
Smart Money
74/100
Bullish
- Market cap
- 146.75B
- P/E ratio
- 14.94
- Dividend yield
- 6.15%
- 52-week range
- $23.62 – $28.75
- Volume
- 27.18M
- Avg. volume
- 68.83M
Price performance
PFE price history
1M range · 20 trading sessions · Daily adjusted prices
PFE closed at $27.96 after 20 trading sessions, up 11.71% for the selected period.
- Last close
- $27.96
- Period change
- +11.71%
- Period low
- $25.03
- Period high
- $28.57
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $28.00 | $28.02 | $27.77 | $27.96 | 27.18M |
| Aug 27, 2026 | $27.97 | $28.18 | $27.83 | $28.02 | 31.17M |
| Aug 26, 2026 | $28.44 | $28.50 | $28.145 | $28.30 | 35.07M |
| Aug 25, 2026 | $27.915 | $28.58 | $27.84 | $28.57 | 31.92M |
| Aug 24, 2026 | $28.10 | $28.1561 | $27.81 | $27.97 | 23.85M |
| Aug 21, 2026 | $27.77 | $28.425 | $27.655 | $28.07 | 37.11M |
| Aug 20, 2026 | $28.00 | $28.16 | $27.645 | $27.79 | 29.3M |
| Aug 19, 2026 | $27.60 | $28.435 | $27.58 | $28.24 | 59.8M |
| Aug 18, 2026 | $27.15 | $27.395 | $27.10 | $27.25 | 34.66M |
| Aug 17, 2026 | $26.76 | $27.02 | $26.55 | $26.87 | 29.26M |
| Aug 14, 2026 | $26.66 | $26.915 | $26.42 | $26.79 | 23.17M |
| Aug 13, 2026 | $26.49 | $26.95 | $26.41 | $26.80 | 35.36M |
| Aug 12, 2026 | $26.385 | $26.435 | $26.18 | $26.31 | 32.59M |
| Aug 11, 2026 | $26.94 | $27.20 | $26.47 | $26.62 | 37.94M |
| Aug 10, 2026 | $26.585 | $27.19 | $26.52 | $27.05 | 49.79M |
| Aug 7, 2026 | $26.22 | $26.76 | $26.0503 | $26.76 | 42.74M |
| Aug 6, 2026 | $26.01 | $26.20 | $25.81 | $26.20 | 51.07M |
| Aug 5, 2026 | $25.50 | $25.81 | $25.30 | $25.81 | 47.06M |
| Aug 4, 2026 | $25.04 | $25.64 | $24.70 | $25.41 | 62.19M |
| Aug 3, 2026 | $25.15 | $25.39 | $24.865 | $25.03 | 41.78M |
Latest PFE news
The latest Smart Investors Daily articles mentioning PFE.
Stock researchResearch & News · Competitors
Loading stock research…